Patents: the reason anyone takes the risk
Spending a billion-plus dollars over a decade, with a 90% chance of failure, only makes sense if success can be rewarded. A patent is the legal device that makes that possible: it grants the inventor a time-limited monopoly — typically 20 years from filing — to exclude others from making or selling the claimed invention. For a new medicine, the most valuable claim is usually on the new chemical entity itself, the active pharmaceutical ingredient.
Generics: copying a small molecule
When the patents and any extra exclusivity expire, anyone may make the molecule. A generic drug is a copy of an off-patent small-molecule medicine. Because the active ingredient is a precisely defined chemical, a generic maker can reproduce the *exact same molecule* — and does not have to repeat the enormous clinical trials. Instead they prove bioequivalence: that their product delivers the same amount of drug into the bloodstream over time as the original.
The effect on price is dramatic. Without trial costs and with many competitors, generics often cost a small fraction of the brand price. This is the deliberate bargain of the system: a company gets a limited window of profit to reward innovation, after which society gets the medicine cheaply, forever.
Biosimilars: why biologics are different
Not every drug is a small molecule. A biologic — for example a monoclonal antibody — is a large, complex protein grown in living cells, and its exact structure depends on the cell line and process used to make it. You cannot simply "copy" it atom for atom the way you copy a small molecule. A follow-on version is therefore not called a generic but a biosimilar: a product *highly similar* to the reference biologic, with no clinically meaningful differences.